Filetype PDF | Posted on 17 Jan 2023 | 3 years ago
Authentication
digital resources
364x Filetype PDF File size 2.96 MB Source: www.unido.org
BOOSTING
PHARMACEUTICAL
PRODUCTION
1
1
“In line with our mandate to promote inclusive
and sustainable industrial development, we
will support efforts to enhance public health
and enable populations to be increasingly
economically productive through the development
of viable high-quality industries in this important
knowledge-intensive sector...”
- LI Yong, UNIDO Director General
22 3
2 3
Introduction Pharmaceutical Sector International Quality Investment and
Strategies, Policies and Standards and Efficient Technology Transfer
Programmes Production
PAGE 6 PAGE 8 PAGE 10 PAGE 12
1 2 3 4
Human Resources Analysis and Research Pharmaceutical
Development Manufacturing
Associations
PAGE 14 PAGE 16 PAGE 18
5 6 7
UNIDO STRATEGY UNIDO LPP PROGRAMME - THEORY OF CHANGE:
INTRODUCTION Against this background, UNIDO is taking its assistance
to the next level by using a programmatic approach. In 2019 2023 2030
Since 2006, UNIDO has provided technical cooperation line with the Theory of Change of UNIDO’s Medium Term
and advisory services to advance local pharmaceutical Programme Framework, a multi-disciplinary team of
production (LPP) in developing countries with a wide UNIDO technical experts ensures effective and coherent
range of public and private sector partners. Under a delivery of the organization’s key LPP services. Proactive Integration* Scale Up + Transformation Outcomes Impact
global project, UNIDO contributed to improving the knowledge management and communications provide the
operational environment and technical capacities of basis for strategic operational planning and coordination LPP acceleration through:
local manufacturers, and helped “mainstreaming” LPP which integrate technical cooperation, policy advice • ro ing numer of companies
as a global development theme. This engagement has and quality-related services with priority partnerships Technical Cooperation, emarking on international Strong progress in
established UNIDO as a leading organization on the LPP for scale up and transformational change. A particular including policy advisory uality standards of production reaching Universal P
agenda, with a strong and vibrant network of partners. focus is given to removing key systemic constraints such and quality- • Increase in access to finance across LI
s
The success of the global LPP project - funded by Germany as lack of finance, technology and access to markets. As related services and technology Sustainale supply of
as a basis to attract additional resources for scale-up such, UNIDO’s support to LPP contributes effectively to • pansion in numer of
s, safe, effective, uality,
and transformational impact - has increased demand for strengthening the health security of LMICs and attaining countries and companies ffective and favorale and affordale essential
UNIDO’s services and allowed it to expand its engagement SDG target 3.8 on “access to safe, effective, quality, and + reuesting and receiving LPP operational environ medicines and vaccines
beyond essential medicines into the local production of affordable essential medicines and vaccines for all”, UNIDO technical assistance ment legal frame ork, as contriution to SD
biologicals and vaccines. while, at the same time, contributing to ISID as enshrined • ro ing commitment of policies, regulations, target – ith a focus
in SDG9. Convening and overnments to implement institutional capacities, … on uality production
Partnerships conducive policies and across LI
s and inclusive and
timeound incentives sustainale industrial
UNIDO SERVICES • Legal frame orks, policies and iation ia SD targets
UNIDO’s global LPP project (2006-2018) confirmed the institutional structures in place ffective access to , ,
THE IMPORTANCE OF LPP * Integrated provision of • usiness emership finance, technology and
need for continued delivery and further expansion of a UNIDO LPP Service Package, markets through strong
tested package of LPP services under a programmatic leveraged through systematic Organiations strengthened and sustainale partner
» More than two billion people worldwide approach. In particular, these include: as asis for strategic to represent and promote LPP ships and stakeholder
cannot get the medicines they need. planning, monitoring • mechanisms and tools
reporting, communications net orks
» Policy advice to formulate and implement advocacy, and learning strengthening advocacy,
pharmaceutical sector strategies, policies and communications and
» LPP can help vulnerable populations, programmes partnerships
especially those in remote rural areas, to
access quality medicines, thus contributing » Technical guidance to companies to achieve
to “leaving no one behind, and reaching international production standards such as Good
the furthest behind first”, the overarching Manufacturing Practices (GMP)
principle of the 2030 Agenda for » Business mentoring to increase production
Sustainable Development. efficiencies and cost savings, and to improve
business planning
» LPP can reduce the dependency on » Promotion of investment and technology transfer
international donations and a shrinking through 1) working with local companies and partners,
number of overseas companies who and 2) matchmaking platforms and activities between
dominate the global market. both North-South and South-South, brokering win-
win arrangements, including through Public-Private
Partnerships
» LPP is easier to control and can help curb » Human resources development to ensure further
the vast influx of sub-standard medicines expansion and long-term sustainability of local
into developing countries. production
» While LPP is wide-spread, most companies » Analysis and research for developing sector policies
operate much below international and strategies, including on the economics of
production and on market data, as a basis for
standards. Helping to upgrade their rational decision making by companies, investors
production contributes directly to and policymakers
people’s health, as well as to inclusive and » Strengthening regional and continental
sustainable industrial development (ISID). pharmaceutical manufacturers associations who
represent and promote the industry, provide services
to its members and engage with decision makers to
address remaining challenges to LPP
66 77
6
no reviews yet
Please Login to review.
